Long-tail research compounds

A single honest entry for the long tail of circulating compounds. The human record varies: a few have early-phase clinical research (TAK-653, an AMPA modulator with randomized human studies; KW-6356/sipagladenant, an adenosine antagonist with Phase 1/2 Parkinson's work; L-THP, a plant alkaloid with human pharmacokinetic and addiction-research data). Others are academic tool molecules (J-147, CMS-121 — curcumin-derived neuroprotection candidates), one-paper wonders (PRL-8-53's single 1970s memory study), Russian-institute designs (GB-115, Nooglutyl, BPAP), and catalog names with no traceable literature or even verifiable identity at all (DADA, Y-134, Compound 7P, ACE-167, and "MK-777/Acetamoren," whose claimed identity has no authoritative source).

Even for the best-studied names here, the human data is early-phase and was collected inside monitored trials for specific indications — none has an efficacy dossier for the cognitive-enhancement uses they are sold for. For the rest, human data ranges from one unreplicated study to literally zero. If one of these later earns a real dossier, it will earn its own entry.

Largely unquantifiable — thin-to-absent safety data is a worse position than "known risks," not a better one. A certificate of analysis can establish chemical identity and purity, but it does not establish clinical safety, efficacy, or chain of custody — and for names with no verifiable identity, even that floor is missing.

US: not FDA-approved for human use; mostly unscheduled. Marketing them for human use may violate the FD&C Act.

Not auto-graded. This entry covers several different drugs, or a use the published research was never about, so no single letter honestly describes it. The reading below is real literature — read it against what this page says, not as a score.

• Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson diseaseJ Hepatol · 2024
• Huperzine ADrugs R D · 2004
• Natural product-based amyloid inhibitorsBiochem Pharmacol · 2017
• Investigational therapies for ischemic stroke: neuroprotection and neurorecoveryNeurotherapeutics · 2011
• Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agentsDrug Test Anal · 2023
• Learning from failureNat Rev Drug Discov · 2010
• Calcium channel blockers and dementiaBr J Pharmacol · 2013
• Pharmacologic management of Alzheimer disease, Part I: Hormonal and emerging investigational drug therapiesAnn Pharmacother · 1999
• Galantamine for Alzheimer's diseaseCochrane Database Syst Rev · 2001
• Dolphin CONTINUE: a multi-center randomized controlled trial to assess the effect of a nutritional intervention on brain development and long-term outcome in infants born before 30 weeks of gestationBMC Pediatr · 2024
• HuCNS-SC (StemCells)Curr Opin Mol Ther · 2006
• Phytochemical Analysis, In Vitro Anticholinesterase, Antioxidant Activity and In Vivo Nootropic Effect of Ferula ammoniacum (Dorema ammoniacum) D. Don. in Scopolamine-Induced Memory Impairment in MiceBrain Sci · 2021